The kit developed by Sansure Biotech for nucleic acid detection of SARS-CoV-2, and influenza A & B virus (PCR-Fluorescence Probing) was approved by the National Medical Products Administration (NMPA) for marketing on December 17. It has also received CE mark and is expected to provide critical support for global COVID-19 prevention and control. According to WHO estimates, influenza causes 3 to 5 […]

On December 8, Sansure Biotech’s SARS-CoV-2 Neutralizing Antibodies Test (Colloidal Gold) and SARS-CoV-2 S-RBD Antibodies Test (Colloidal Gold) passed CE certification and received the certificate. This is the first batch of antibody products in the company’s immune product line to receive international authoritative registration certificate following the antigen detection kits receiving CE certification, which further enriches the company’s immune product […]

On local time November 26, WHO held an emergency session and released a statement in which the SARS-CoV-2 variant B.1.1.529 was listed as a “Variant of Concern” and named after the Greek letter Omicron. According to WHO, the Omicron variant was first reported in South Africa. Preliminary studies showed that the variant has increased the risk of SARS-CoV-2 infection in […]

On November 8, Sansure and KHB signed the Letter of Intent for Investment Framework, to establish cooperation in chemiluminescence immunization subdivision to draw on each other’s strengths and achieve win-win results. According to the agreement, Sansure and KHB jointly invest 50 million yuan to establish a joint venture company “Sansure Immunotech” (proposed), with each side holding 50% of the equity. […]

On October 10, Sansure Biotech Inc. won the Medical Innovation Award in the G20 Innovation Alliance Forum held in Sorrento, Italy, making it the only Chinese company receiving this honor. This first ever event in the history of G20 was hosted by the rotating presidency Italy this time, and it was dedicated to sharing ideas and innovative solutions in response […]